There has been an increasing interest in technological interventions in Parkinson’s disease (PD), particularly with regard to wearable technologies. Numerous detailed systematic reviews have recently been published examining the use of wearable technologies for specific aspects of PD, such as diagnosis or monitoring.
CONy President, Prof. Amos D. Korczyn, a distinguished figure in the field of neurology, shares an update on the 18th World Congress on Controversies in Neurology congress, held in the city of London, UK, brought together leading experts to debate and discuss the most contentious issues within neurology. Prof. Korczyn, with his extensive background in neurodegenerative diseases and his role in shaping discussions at CONy for many years, offers us unique insights into the ground-breaking developments and debates that marked this year's event.
Aquaporin-4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) is an autoantibody-mediated, relapsing disease affecting the central nervous system. Relapse-preventive treatment is crucial because each single attack can result in severe disability.
Multiple sclerosis presents various challenges, leading to an exploration of fluid biomarkers that could provide insights into disease diagnosis, prognosis and treatment response. This editorial focuses on a few biomarkers that may be useful at different stages of multiple sclerosis, reviewing the evidence, potential uses and challenges to overcome for their clinical application.
Education, Conference Coverage and Articles
Parkinson’s disease (PD) is a complex neurodegenerative condition that predominantly affects older people, with a rising prevalence worldwide.1,2 There are many on-going challenges and unmet needs in PD: difficulties in making an accurate diagnosis (particularly in the early stages ...
What is the Stroke Action Plan for Europe? Stroke is one of the most enormous burdens to healthcare services.1 Despite our combined efforts, it affects more than one million people annually in Europe. Although we have abundant knowledge regarding stroke ...
Welcome to the latest edition of touchREVIEWS in Neurology. We are excited to present a collection of articles that showcase the latest advancements and diverse perspectives in neurological research and treatment. This issue features insightful reviews and editorials from esteemed ...
Neuromyelitis optica spectrum disorders (NMOSD) are a group of relapsing autoimmune diseases of the central nervous system. The clinical hallmarks of NMOSD are myelitis and optic neuritis; however, a wider clinical spectrum has been recognized.1 The majority of patients with ...
Watch leading experts explain the shifting diagnostic paradigm in Alzheimer’s disease using case studies demonstrating the utility of biomarkers
Watch leading experts discuss recent developments in Alzheimer’s disease, including the use of biomarkers.
Watch leading spinal muscular atrophy (SMA) experts discuss current trends in pharmacologic and non-pharmacologic therapy use, barriers to use of these standards of care, and potential solutions to improve access as patients age.
Share your knowledge, influence clinical practices and enhance patient care in Neurology today!
Affecting over 70 million patients worldwide, epilepsy is a chronic neurological disorder characterized by intermittent bursts of hyper-synchronous neuronal discharges.1 The manifestations are variable but reflective of the unique milieu and biology of epileptogenic foci.2 Pharmacological treatment with antiepileptic drugs (AEDs) ...
Rescue medications are an important part of the treatment regimen for patients with intractable epilepsy, specifically those who experience seizure clusters or prolonged seizure episodes. Rescue medications are prescribed to end seizure activity quickly and effectively in order to prevent ...
Parkinson’s disease (PD) is characterized by prodromal and clinical stages; the clinical phase is characterized by a constellation of motor and non-motor symptoms (NMS).1 Despite the extensive discussions and publications of the clinical heterogeneity of PD,2 the precise heterogeneous ...
Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory autoimmune disease of the central nervous system (CNS) with a worldwide distribution.1 The first clinical description of NMOSD was made a century ago by Devic and Gault, who documented patients with ...
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder characterized by the degeneration of nigrostriatal dopaminergic neurons, with its incidence increasing globally.1 With disease progression, the benefit from medications shortens, and symptom control becomes strictly dependent on peripheral levodopa (...
Introduction The term 'stroke' is used to describe an adverse clinical state involving interference of blood circulation to the brain due to obstruction or rupture of blood vessels.1 Stroke was previously categorized into a cardiovascular disorder until the release of ...
Multiple sclerosis (MS) is a complex disease that can pose significant challenges in diagnosis, monitoring and treatment. Over the years, the quest for more precise and accessible diagnostic tools has led to the exploration of different fluid biomarkers in cerebrospinal ...
In the latest edition of touchREVIEWS in Neurology, we are pleased to present a collection of insightful articles that highlight the current landscape and future directions in neurological research and treatment. Firstly, Rajvinder Karda opens this issue with a compelling ...
Duchenne muscular dystrophy (DMD) is an X-linked recessive, progressive and universally fatal disease in the spectrum of dystrophinopathies,1 with an incidence of 21.4 patients in 100,000 live male births worldwide.2,3 Historically, patients with DMD would lose ambulation by the age of 10 due ...
Friedreich’s ataxia (FRDA), a neurodevelopmental and progressive neurodegenerative disease, is the most common inherited form of ataxia, with disease incidence as high as 1 in 29,000 in Caucasian populations.1 Patients typically present with ataxia from ages 7 to 15 years and lose the ...
Huntington’s disease (HD) is a genetic neurodegenerative disease that can affect movement, cognition and mental health. It is caused by a dominant mutation in the huntingtin gene, HTT. HD is estimated to occur in 5–10 people per 100,000 yearly, worldwide.1 Pridopidine (...
Shining a light on the burden of migraine and exploring real-world evidence on anti-CGRP antibodies.
Learn about the latest advancements and current barriers in genetic counseling and testing from expert speaker, Jennifer Roggenbuck.
Watch leading experts discuss advances in the early diagnosis and treatment of Alzheimer's disease in this engaging symposium, originally presented at the Spanish Neurological Society.
Introducing the Editorial Board of touchREVIEWS in Neurology, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.
Multiple sclerosis
Attending Neurologist at Cooper University Hospital, Cooper Neurological Institute, Cherry Hill, NJ, USA, Professor of Neurology at Cooper Medical School of Rowan University, Camden, NJ, USA, and Emeritus Professor of Neurology in the Academic Unit of Mental Health and Clinical Neurosciences at the University of Nottingham, Nottingham, UK
Prof. Cris S Constantinescu is the co-Editor-in-Chief of touchREVIEWS in Neurology. Cris Constantinescu is Attending Neurologist at Cooper University Hospital, Cooper Neurological Institute, Cherry Hill, NJ, USA, Professor of Neurology at Cooper Medical School of Rowan University, Camden, NJ, USA, and Emeritus Professor of Neurology in the Academic Unit of Mental Health and Clinical Neurosciences at the University of Nottingham, Nottingham, UK. He graduated with an MD from Boston University School of Medicine, USA, in 1988. As a recipient of the physician-scientist award from the National Institutes of Health, USA, he completed a PhD in immunology at the University of Pennsylvania in 1998. He has completed an internship and a residency in neurology and fellowships in neuroimmunology and neurorehabilitation. He was appointed honorary consultant neurologist and senior lecturer in neurology at the University of Nottingham 2000–2001. In 2004, he was appointed Professor of Neurology and Chair in Neurology at the University of Nottingham, a post he held until 2021. He has authored or co-authored over 200 articles in international journals. His research interests are immune regulation in inflammatory diseases of the nervous system, in particular multiple sclerosis, neuroimaging, clinical trials and cognitive neurology. He is currently involved in the care of numerous patients with neuroimmunological and neurodegenerative diseases.
Neuromuscular diseases
Professor and Division Chief for Neuromuscular Medicine at the Department of Neurology at Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA
Said R Beydoun, MD, FAAN, is Professor and Division Chief for Neuromuscular Medicine at the Department of Neurology at Keck School of Medicine, University of Southern California (USC). He is Program Director of the Clinical Neurophysiology Fellowship. As a principal investigator, Dr Beydoun has participated in multiple research clinical trials. His clinical and research areas of expertise in the field of neuromuscular medicine include amyotrophic lateral sclerosis (ALS), myasthenia gravis, peripheral neuropathy (including chronic inflammatory demyelinating polyneuropathy), multifocal motor neuropathy and transthyretin-related amyloid neuropathy. He has published in several scientific journals on topics related to neuromuscular diseases and is co-Editor-in-Chief of touchREVIEWS in Neurology. He is an elected fellow of the American Academy of Neurology and a fellow of the American Association of Neuromuscular and Electrodiagnostic Medicine; a member of the medical/scientific advisory board of the Myasthenia Gravis Foundation of America; Medical Director of the Certified ALS Treatment Center of Excellence at Keck USC; and holds board certification by the American Board of Psychiatry and Neurology in neurology, clinical neurophysiology, neuromuscular medicine and pain medicine.
Movement disorders
Professor of Neurology/Movement Disorders at King’s College Hospital and King’s College London and Director of the Parkinson Foundation International Centre of Excellence at King’s College London, UK
Prof. K. Ray Chaudhuri is Professor of Neurology/Movement Disorders at King’s College Hospital and King’s College London and Director of the Parkinson Foundation International Centre of Excellence at King’s College. He is Chairman of the Industry Engagement Committee, and Co Chair Task force of the Parkinson Wellness committee of the Movement Disorders Society (MDS and Ex Chair Membership and Public Relations Committee of the Movement Disorders Society (MDS), was a member of the MDS Congress Scientific Programme Committee (2013-2017) and is Founder and Ex Chairman and current steering group member of the MDS Non-Motor Parkinson’s Disease Study Group and a member of the MDS-ES Education committee and Evidence Based Medicine committee (Nonmotor symptoms). He was the founder -Editor-in-Chief of the njp Parkinson’s Disease (2020 impact factor >8), Guest Editor for special editions of Frontiers in Neurology and Journal of Parkinson’s Disease, reviewer for all mainstream movement disorders journals as well as JAMA, Neurology, Annals of Neurology, BMJ, Brain, Lancet, and Journal of Neurology, Neurosurgery, and Psychiatry. He serves as an advisor (MHRA health technology and scientific advisor) to the UK National Institute for Health and Care Excellence, NHS England, General Medical Council as well as Parkinson’s UK and Parkinson’s Europe.
Prof. Chaudhuri is the author of over 500 articles, co-editor of 5 books on Parkinson’s disease and restless legs syndrome, and winner of the British Medical Association Book Awards commendation in 2015 and 2017. He is also the recipient of 2018 Jay Van Andel Award Outstanding Achievement in Parkinson’s Disease Research (pioneering holistic assessments and non-motor subtypes), as well as National Institute for Health Research/Royal College of Physicians award for outstanding research leadership in 2017. He was elected honorary member of the Movement Disorders Society in 2021, Honorary Professor Brasov University, Honorary Professor SRM University, India and received the UK NHS Gold merit award in 2021 for excellence in research and clinical service. In 2023 he was featured as “role model” in British Medical Journal. He has been a guest lecturer worldwide, including in Japan, China, Taiwan, Vietnam, Thailand, Singapore, Australia, India, Africa, the US, Russia, and Europe. In 2022/2023 he is ranked fourth in the world for Parkinson’s publications/expertise and expertise since 2014 and no 1 in the UK (expertscape: Parkinson’s disease). In 2024, an independent review in Frontiers journal by LI et al rated KRC as the one with most publications globally in nonmotor Parkinson’s since 2013 (Li et al , DOI 10.3389/fnagi.2024.1335550). In 2024 Prof. Chaudhuri will inaugurate the Kings Parkinson Charity dedicated to research to promote day to day care for People with Parkinson and their carers in conjunction with Sir Nicholas Mostyn, founder of the BBC endorsed Movers and Shakers expert patients group.
Headache Disorders
Vice President of the New England Institute for Neurology and Headache (NEINH) in Stamford, CT, and Professor of Neurology at the Geisel School of Medicine at Dartmouth, NH, USA
Stewart J Tepper, MD, FAHS is Vice President of the New England Institute for Neurology and Headache (NEINH) in Stamford, Connecticut and Professor of Neurology at the Geisel School of Medicine at Dartmouth. Dr Tepper received his undergraduate degree in the study of the nervous system/psychobiology from Yale and attended Cornell University Medical College. He completed his Neurology residency at Harvard.
Dr Tepper has published more than 480 peer-reviewed manuscripts, editorials, and books on Headache Medicine. He serves on the Executive Board of Directors and is the Corporate Liaison for the American Headache Society. He also serves on the AHS Education, Exhibits, and Finance Committees and on the Governance Committee for the American Migraine Foundation.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.